Literature DB >> 1280634

Human carcinoma cells synthesize and secrete tenascin in vitro.

H Kawakatsu1, R Shiurba, M Obara, H Hiraiwa, M Kusakabe, T Sakakura.   

Abstract

Tenascin is an extracellular matrix glycoprotein produced in response to epithelial-mesenchymal interactions that initiate fetal organogenesis, and it is also found in the stroma of benign and malignant neoplasms. Thirty-five human cell lines representing a variety of cancers were examined by immunoprecipitation and polyacrylamide gel electrophoresis of radiolabeled tenascin proteins from conditioned media. Two forms of tenascin with relative molecular masses of 190,000 and 250,000 were identified. Eight cell lines produced both forms. With the exception of myeloid and lymphoid leukemias and Burkitt's lymphoma, all of the mesodermal and neuroectodermal tumor lines were found to synthesize tenascin. Unexpectedly, tenascin was secreted by several mammary and colonic adenocarcinomas as well as by a line derived from normal mammary epithelial cells, and in some cases increased production was induced by transforming growth factor beta in serum-free medium. Cells producing fibronectin but not tenascin attached and spread on plastic culture dishes, while those producing tenascin alone remained suspended in the medium or were rarely attached. Tenascin also inhibited fibronectin-mediated adhesion of MCF7 breast carcinoma cells in vitro. The results suggest that tenascins synthesized and secreted by some cancer cells, especially those of epithelial origin, may have specific roles in determining tumor cell adhesion and ultimately the ability to form invasive outgrowths.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280634      PMCID: PMC5918669          DOI: 10.1111/j.1349-7006.1992.tb02724.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


tenascin extracellular matrix fibronectin sodium dodecyl sulfatepolyacrylamide gel electrophoresis transforming growth factor beta epidermal growth factor phosphate‐buffered saline fetal calf serum bovine serum albumin glioma‐mesenchymal extracellular matrix antigen relative molecular mass kilodalton
  34 in total

1.  Identification and characterization of the promoter for the cytotactin gene.

Authors:  F S Jones; K L Crossin; B A Cunningham; G M Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

2.  Two contrary functions of tenascin: dissection of the active sites by recombinant tenascin fragments.

Authors:  J Spring; K Beck; R Chiquet-Ehrismann
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

3.  Exogenous tenascin inhibits mesodermal cell migration during amphibian gastrulation.

Authors:  J F Riou; D L Shi; M Chiquet; J C Boucaut
Journal:  Dev Biol       Date:  1990-02       Impact factor: 3.582

4.  Murine tenascin: cDNA cloning, structure and temporal expression of isoforms.

Authors:  Y Saga; T Tsukamoto; N Jing; M Kusakabe; T Sakakura
Journal:  Gene       Date:  1991-08-15       Impact factor: 3.688

5.  Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies.

Authors:  A Siri; B Carnemolla; M Saginati; A Leprini; G Casari; F Baralle; L Zardi
Journal:  Nucleic Acids Res       Date:  1991-02-11       Impact factor: 16.971

6.  A cDNA clone for cytotactin contains sequences similar to epidermal growth factor-like repeats and segments of fibronectin and fibrinogen.

Authors:  F S Jones; M P Burgoon; S Hoffman; K L Crossin; B A Cunningham; G M Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

7.  Tenascin during gut development: appearance in the mesenchyme, shift in molecular forms, and dependence on epithelial-mesenchymal interactions.

Authors:  E Aufderheide; P Ekblom
Journal:  J Cell Biol       Date:  1988-12       Impact factor: 10.539

8.  Localization during development of alternatively spliced forms of cytotactin mRNA by in situ hybridization.

Authors:  A L Prieto; F S Jones; B A Cunningham; K L Crossin; G M Edelman
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

9.  Tenascin is associated with chondrogenic and osteogenic differentiation in vivo and promotes chondrogenesis in vitro.

Authors:  E J Mackie; I Thesleff; R Chiquet-Ehrismann
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

10.  Changes in the distribution of tenascin during tooth development.

Authors:  I Thesleff; E Mackie; S Vainio; R Chiquet-Ehrismann
Journal:  Development       Date:  1987-10       Impact factor: 6.868

View more
  8 in total

1.  Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells.

Authors:  Keiki Nagaharu; Xinhui Zhang; Toshimichi Yoshida; Daisuke Katoh; Noriko Hanamura; Yuji Kozuka; Tomoko Ogawa; Taizo Shiraishi; Kyoko Imanaka-Yoshida
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 2.  Stromal biomarkers in breast cancer development and progression.

Authors:  Jenny A Rudnick; Charlotte Kuperwasser
Journal:  Clin Exp Metastasis       Date:  2012-06-10       Impact factor: 5.150

3.  Tenascin expression in primary and recurrent breast carcinomas and the effect of tenascin on breast tumor cell cultures.

Authors:  A M Tokés; S Paku; S Tóth; E Paál; J Kulka; J Tóth; A Telekes
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 4.  Tenascins, a growing family of extracellular matrix proteins.

Authors:  R Chiquet-Ehrismann
Journal:  Experientia       Date:  1995-09-29

5.  A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis.

Authors:  Pedro Correa de Sampaio; David Auslaender; Davia Krubasik; Antonio Virgilio Failla; Jeremy N Skepper; Gillian Murphy; William R English
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

Review 6.  Tenascin C in metastasis: A view from the invasive front.

Authors:  Camille M Lowy; Thordur Oskarsson
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

7.  Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy.

Authors:  Giuseppe Gritti; Andrea Gianatti; Fiorella Petronzelli; Rita De Santis; Chiara Pavoni; Riccardo Lorenzo Rossi; Laura Cattaneo; Luigi Giusto Spagnoli; Silvia Ferrari; Andrea Rossi; Anna Maria Barbui; Alessandro Rambaldi
Journal:  Oncotarget       Date:  2018-01-03

8.  Specific expression of tenascin in human colonic neoplasms.

Authors:  T Sakai; H Kawakatsu; N Hirota; T Yokoyama; T Sakakura; M Saito
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.